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Abstract
Background: Inflammation, metabolism, and epigenetic modulation are highly interconnected processes that can
be altered during tumorigenesis. However, because of the complexity of these interactions, direct cause and effect
during tumorigenesis have been difficult to prove. Previously, using a murine model of inflammation-induced colon
tumorigenesis, we determined that the promoter of the catalytic subunit of DNA polymerase gamma (Polg) is DNA
hypermethylated and silenced in inflammation-induced tumors, but not in non-inflammation-induced (mock)
tumors, suggesting that inflammation can induce silencing of Polg through promoting DNA methylation during
tumorigenesis. Polg is the only mitochondrial DNA polymerase and mutations in Polg cause mitochondrial diseases
in humans. Because of the role of mitochondria in metabolism, we hypothesized that silencing of Polg in
inflammation-induced tumors would result in these tumors having altered metabolism in comparison to mock
tumors.
Methods: Inflammation-induced and mock colon tumors and colon epithelium from a mouse model of
inflammation-induced colon tumorigenesis were assayed for alterations in Polg expression, mitochondria, and
metabolism. Organoids derived from these tissues were used to study the direct effect of loss of Polg on
mitochondria and metabolism.
Results: We demonstrate that inflammation-induced tumors with reduced Polg expression have decreased
mitochondrial DNA content and numbers of mitochondria compared to normal epithelium or mock tumors.
Tumoroids derived from mock and inflammation-induced tumors retained key characteristics of the original tumors.
Inflammation-induced tumoroids had increased glucose uptake and lactate secretion relative to mock tumoroids.
shRNA-mediated knockdown of Polg in mock tumoroids reduced mtDNA content, increased glucose uptake and
lactate secretion, and made the tumoroids more resistant to oxidative stress.
Conclusions: These results suggest that inflammation-induced DNA methylation and silencing of Polg plays an
important role in the tumorigenesis process by resulting in reduced mitochondria levels and altered metabolism.
An enhanced understanding of how metabolism is altered in and drives inflammation-induced tumorigenesis will
provide potential therapeutic targets.
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Background
Inflammation is known to directly contribute to epigen-
etic and metabolic alterations as well as tumor formation
[1]. Furthermore, epigenetics and metabolism affect each
other [2, 3]. For example, epigenetic alterations, includ-
ing DNA methylation and histone modification, can re-
sult in heritable changes in expression of genes involved
in metabolism without altering the DNA sequence of
these genes. Additionally, alterations in metabolism can
affect the availability of metabolites that act as cofactors
or inhibitors of epigenetic enzymes.
Metabolism differs in cancer cells compared to normal
cells with one of these changes being an increase in
glycolysis [4]. This change in metabolism in cancer cells
supports their higher proliferative rate and increased
need to generate macromolecules for accelerated mi-
tosis. One hallmark of increased glycolysis is an increase
in glycolytic flux, which allows cancer cells to take up
high levels of glucose even in the presence of physio-
logical levels of ATP [5].
Mitochondria produce ATP through oxidative phos-
phorylation (OXPHOS) and in the process generate
reactive oxygen species (ROS), redox molecules, and me-
tabolites. They can sense cellular stress and assist cells
in adapting to the environment making them important
to the function of both normal and cancer cells. Because
of their multiple cellular functions, the role of mitochon-
dria in carcinogenesis is complex and can vary between
cancers. While some cancers depend on mitochondrial
respiration, other cancers have dysregulated mitochon-
dria resulting in less efficient OXPHOS [6]. DNA
polymerase γ (POLG) is the only mitochondrial DNA
polymerase and is involved in the replication and repair
of mitochondrial DNA (mtDNA). Furthermore, POLG is
the only DNA polymerase capable of maintaining mito-
chondrial numbers [7]. POLG is a heterodimeric enzyme
consisting of the catalytic core encoded by the POLG
gene and an accessory subunit encoded by POLG2.
Mutations in POLG result in reduced mitochondria and
mitochondrial disorders in humans [8]. Experimentally
reducing POLG expression levels results in decreased
mtDNA levels [9]. Each mitochondrion contains mul-
tiple copies of mtDNA, and the copy number changes in
response to energy demands. Expression of POLG and
mtDNA copy number are controlled during develop-
ment with high energy-consuming cells having a higher
mtDNA copy number than lower energy cells [10]. DNA
methylation of the promoter CpG island of POLG has
been associated with reduced gene expression and
decreased mtDNA copy number in highly proliferative
versus terminally differentiated cells and several cancer
cell lines [10, 11]. While DNA hypermethylation of Polg
in human colorectal cancer has not been specifically
studied, data from The Cancer Genome Atlas (TCGA)
suggests that some colorectal cancers have increased
levels of Polg promoter DNA methylation [12]. Further-
more, mutations in POLG have been found in human
breast cancers and are associated with decreased
mtDNA levels and decreased mitochondrial activity [13].
We use a mouse model of inflammation-induced
tumorigenesis to study the initiation of DNA methyla-
tion by inflammation. In this model, mice are infected
with a human commensal bacterium, enterotoxigenic
Bacteroides fragilis (ETBF). ETBF infection induces
acute followed by chronic inflammation in the distal
colon [14]. Infection of multiple intestinal neoplasia
(Min) mice, which are heterozygous for loss of the
tumor suppressor gene adenomatous polyposis (Apc),
results in Th17 inflammation-driven tumorigenesis in
the distal colon [15]. ETBF-infected Min mice develop
on average 13 distal colon tumors (ETBF Min tumors)
as compared to mock-infected mice that only occasion-
ally develop colon tumors (Mock Min tumors––0.3
tumors per mouse) [16]. Using this model, we have dem-
onstrated that inflammation-induced tumors have DNA
hypermethylated regions relative to epithelium from
mock-infected mice (mock Min epithelium) that are not
present in non-inflammation-induced tumors from
mock-infected mice (mock Min tumors) [16]. Inflamed
epithelium isolated from ETBF-infected mice after the
removal of tumors (ETBF Min epithelium) has an
intermediate level of DNA hypermethylation at regions
altered in ETBF Min tumors. Importantly, we demon-
strated that the initiation of epigenetic changes is
dependent on the mismatch repair protein MSH2 (MutS
homolog 2) recruiting epigenetic proteins to sites of
inflammation-induced oxidative damage. Mice lacking
MSH2 in their intestinal epithelial cells (Msh2l/lVCMin)
are deficient in mismatch repair, and ETBF infection of
these mice results in an increase in tumorigenesis that is
localized to the same region of the colon as in Min mice
(a mean of 30 distal colon tumors per mouse) [16].
Interestingly, these tumors (ETBF Msh2l/lVCMin
tumors) have very few regions with DNA hypermethyla-
tion and their genome-wide methylation profiles are
more similar to mock Min tumors than ETBF Min tu-
mors. Polg was one of the genes found to be specifically
silenced through promoter CpG-island DNA hyperme-
thylation in inflammation-induced tumors with wildtype
MSH2, and a lack of MSH2 in intestinal epithelial cells
prevented Polg methylation and loss of expression in
inflammation-induced tumors [16].
Because of POLG’s role in mitochondrial function, we
hypothesized that reduced expression of Polg would
result in reduced mtDNA and altered metabolism in
inflammation-induced tumors as compared to non-
inflammation-induced tumors. This study reports a
novel functional role for Polg methylation during
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inflammation-driven tumorigenesis, specifically a reduc-
tion in mitochondria that is correlated with an increase
in glucose uptake and resistance to oxidative stress.
Methods
Animal model
MinApcΔ716± and Msh2l/lVCMin mice were handled and
inoculated with ETBF as described previously [15, 16].
For all experiments, both males and females were used,
mice were randomized between mock and ETBF groups,
and mice of different genotypes were cohoused. Individ-
ual tumors were removed from dissected colons at 4 or
8 weeks post-infection with the aid of a dissecting
microscope and stored at − 80 °C until further analysis.
Distal (0–2 cm measured from the rectum) epithelium
was collected by scraping the mucosal surface of the
dissected colon (after removal of any tumors), washed
three times in PBS, and then subjected to the indi-
cated protocol. Such scraping has been shown to be
an effective method to obtain samples of intestinal
epithelial cells [17].
Quantitative methylation-specific PCR (qMSP) and mtDNA
content
Isolated DNA (QIAamp DNA Micro Kit, Qiagen)
was bisulfite-treated (EZ DNA methylation-Gold kit,
Zymo Research), and qMSP assays were performed as
described previously [16]. Quantification of mtDNA levels
relative to nuclear DNA (ApoB– Apolipoprotein B)
was performed using qPCR and the delta Ct method
[18, 19]. See Additional file 1: Table S1 for primers
used.
Gene expression
RNA was prepared from epithelium, tumors, or orga-
noids using Trizol followed by cleanup with a RNeasy
kit (Qiagen). cDNA was prepared, and qPCR was done
using TaqMan assays (see Additional file 1: Table S1 for
assays used). Expression of candidate genes was normal-
ized to expression of a housekeeping gene (PPIA).
Transmission electron microscopy
Four weeks post-infection colons were dissected,
opened, and rinsed with PBS. A 1-mm section was cut
from the most distal 0–0.5 cm region and fixed on ice in
2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M
sodium cacodylate, and pH 7.2 for 16 h. While on ice,
the samples were processed further by being put into
four changes of buffer to remove fixative, followed by
2% osmium tetroxide in 0.1 M sodium cacodylate buffer,
pH 7.2 for 2 h, two changes of buffer to remove residual
osmium tetroxide, and through a graded ethanol dehy-
dration series to 100% ethanol. At room temperature,
the samples were placed in three changes of 100%
ethanol, 2:1, 1:1, 1:2 of ethanol/propylene oxide, 100%
propylene oxide, infiltrated first with 1:1, 1:3, 1:6 propyl-
ene oxide/Embed 812 resin (Electron Microscopy
Sciences, Hatfield, PA), and then with three changes of
100% resin before polymerization at 65 °C for 18 h. The
polymerized blocks were sectioned at 70 nm thickness
using a Leica Ultracut UCT ultramicrotome. Sections
were placed on 300-mesh copper grids. The grids were
stained first with saturated uranyl acetate, washed with
water, and then with lead citrate. The grids were viewed
with a JEOL company JEM-1010 transmission electron
microscope and photographed using a Gatan 1 k × 1 k
model 794 MultiScan camera. A single tumor was
imaged per condition with five images taken per sample
by a blinded investigator.
Metabolomic analysis
Metabolomic analysis was performed using gas
chromatography-mass spectrometry (GC-MS) as previ-
ously described with slight modifications [20]. Namely,
~ 5–10 mg of distal colon epithelium or tumors were
washed twice in ice-cold PBS; then, metabolites were ex-
tracted with 800 μL of 90% cold methanol containing
2 μg/mL of succinic acid-2,2,3,3-d4 as an internal
standard using the Omni Bead Ruptor 24 homogenizer
(Omni International), and dried with a Speed-Vac. Dried
extracts were derivatized with O-methoxylamine
hydrochloride and N-methyl-N-trimethylsilyltrifluorace-
tamide containing 1% trimethylchlorosilane, respectively.
Derivatized samples were analyzed in an Agilent 6890
GC-5973iMS equipment with a 30-m Phenomex ZB5-5
MSi column with a 5-m long guard column. Raw data
were normalized with the internal standard and tissue
mass.
Organoids
Organoids were derived from mock distal colon epithe-
lium (colonoids) or mock or inflammation-induced Min
colon tumors (tumoroids) as demonstrated previously
and grown in basal growth media containing EGF (epi-
dermal growth factor), Noggin, R-Spondin1, and Wnt3a
(colonoids) or EGF and Noggin (tumoroids) [21, 22].
shRNA-mediated Polg knockdown was performed by
dissociating tumoroids into single cells using TrypLE,
plating in Matrigel and incubating in media containing
polybrene plus nontarget (NT) or Polg-concentrated
lentivirus for 2 h. Then, the media were changed to
normal tumoroid medium supplemented with 10 μM
Y27632. Forty-eight hours later, media were replaced
with fresh media containing 4 μg/ml puromycin. Knock-
down organoids were passaged at least one time before
performing downstream assays.
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Proliferation assay
Tumoroids were disassociated into single cells and 4000
cells in 25 μL Matrigel were plated per well of a 48-well
plate. On the indicated day, tumoroids were lysed by
homogenization in 200 μL Lactate Assay Buffer (BioVi-
sion). The DNA concentration of the lysate was then de-
termined using the Qubit dsDNA HS assay (Invitrogen),
which is highly selective for DNA over RNA. Readings
were found to be proportional to but more sensitive
than cell numbers (data not shown). A similarly treated
well without any cells added was used as a blank for the
readings. Total DNA content was calculated by multiply-
ing the concentration of DNA by the total volume of
buffer.
Glucose uptake, glucose depletion, and lactate secretion
Glucose uptake assays were performed using the Glu-
cose Uptake Colorimetric Assay Kit (BioVision) with
some modifications. After 5 days of growth, tumoroids
were incubated in 250 μL KRPH buffer (20 mM HEPES,
5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM
NaCl, 4.7 mM KCl, pH 7.4) for 40 min followed by the
addition of 25 μL of 10 mM 2-DG (2-deoxy-D-glucose)
and an additional 20-min incubation. Washed tumoroids
were then removed from the Matrigel by pipetting up
and down in cold PBS and lysed in extraction buffer. A
2-DG6P standard curve was performed during each ex-
periment and used to calculate 2-DG uptake. As per the
manufacturer’s recommendation, protein concentration
(BCA) assays were performed on the same cell lysate
from each sample that was used for the glucose uptake
assay to determine the protein concentration, which was
then used to normalize the 2-DG uptake.
The same wells of tumoroids were used for glucose
depletion and lactate secretion assays. Media were
collected from each tumoroid well at the indicated day
post-plating and used immediately for the assays.
Glucose levels were measured using 2 μL media and the
Glucose (HK) Assay Kit (Sigma-Aldrich) following the
manufacturer’s directions. Media from a similarly treated
well without any cells added were used to determine the
starting glucose levels. The glucose standard provided
with the kit was used during each experiment to calcu-
late glucose levels. Glucose depletion was calculated by
subtracting the glucose levels in the media of a given
well from the media from the no cells well. The concen-
tration of DNA in each well was determined as in the
“Proliferation assay” section and used to normalize the
depleted glucose levels. To determine lactate levels,
media were diluted 1:10 or 1:20 in lactate assay buffer
and 2 μL was assayed with the Lactate Colorimetric/
Fluorometric Assay Kit (BioVision) following the manu-
facture’s protocol. A L(+)-Lactate standard was assayed
during each experiment and used to calculate lactate
levels. Lactate levels were normalized to DNA concen-
tration as above. For NT and Polg KD tumoroids, lactate
levels in media of wells containing tumoroids were
determined as above at day 5 post-plating.
Tumoroid viability
Seventy-two hours after the addition of PBS or 0.5 mM
H2O2 to the media of tumoroid cultures, the media were
removed and 250 μL of KRPH buffer was added plus
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) to a final concentration of 500 μg/ml and
incubated at 37 °C for 1 h. Matrigel and MTT were
solubilized as previously described [23].
Statistical analysis
Expression data, qMSP, mtDNA content, metabolite
levels, glucose uptake, and cell viability are presented as
the mean ± standard error (SEM). Data are evaluated by
Mann-Whitney U test and considered statistically signifi-
cant with a p value < 0.05. Sample sizes are indicated in
associated figure legends for assays using tumor tissue.
For all assays performed with organoid experiments were
performed three times with two to three biological repli-
cates per experiment. The mean ± SEM is computed
using all biological replicates from all experiments.
Results
DNA methylation of Polg is associated with reduced
mtDNA content in inflammation-induced colon tumors
Using methyl CpG-binding domain sequencing (MBD-seq),
we previously found that inflammation-induced tumors
(ETBF Min tumors) collected from Min mice 8 weeks
post-ETBF infection have unique DNA hypermethylated
regions that are mostly not hypermethylated in
non-inflammation-induced tumors (mock Min tumors)
[16]. Additionally, we demonstrated that in mice lacking
expression of the mismatch repair protein MSH2 in their
intestinal epithelium, the inflammation-induced DNA
hypermethylation and expression alterations in tumors
were reduced as compared to ETBF Min tumors [16]. The
CpG-island containing promoter of Polg is one of regions
specifically DNA hypermethylated in ETBF Min tumors. As
POLG is the only mitochondrial DNA polymerase involved
in the replication and repair of mitochondrial DNA, and
mitochondria play a critical role in tumorigenesis, tumor
progression, and metabolic regulation, we decided to
explore the association between the DNA methylation of
Polg and tumor metabolism. Tumors can be macrodis-
sected as early as 4 weeks post-infection in our mouse
model. Therefore, we assayed Polg DNA methylation in
early tumors and epithelium from Min and Msh2l/lVCMin
mice as well as 8-week tumors and epithelium for compari-
son. Four- and 8-week ETBF Min tumors had significantly
higher levels of Polg DNA methylation than epithelium
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from mock-infected mice (mock Min epithelium) (Fig. 1a).
In contrast, ETBF Min epithelium and mock Min and
ETBF Msh2l/lVCMin tumors had increased Polg DNA
methylation compared to mock Min epithelium 8 weeks
post-mock infection, but not at 4 weeks, and this increase
in DNA methylation was still significantly less than the Polg
methylation in ETBF Min tumors. No significant changes
in Polg promoter methylation were detected in inflamed
epithelium from Msh2l/lVCMin mice (Fig. 1a). Lack of
DNA methylation in the CpG island containing promoter
of Gapdh in all samples serves as a negative control.
Promoter CpG-island DNA hypermethylation is
known to be associated with reduced gene expression.
Polg expression was decreased in 4- and 8-week ETBF
Min tumors relative to mock and ETBF Min epithelium
and mock Min and ETBF Msh2l/lVCMin tumors
(Fig. 1b). Confirming the relationship between DNA
methylation and expression, Polg expression in 8-week
ETBF Min tumors was less than 4-week ETBF Min tu-
mors. Additionally, Polg expression was only decreased in
ETBF epithelium and mock Min and ETBFMsh2l/lVCMin
tumors versus mock epithelium 8 weeks post-infection
when there is a corresponding increase in DNA
methylation. There was a trend towards reduced expres-
sion of Polg in ETBF Msh2
l/l
VCMin epithelium 8 weeks
post-ETBF, but the change was not statistically significant
(Fig. 1b).
Because reduced expression of Polg has been associ-
ated with reduced mtDNA content [9], we assayed
mtDNA content relative to genomic DNA content in the
various tissue types. At 4 and 8 weeks post-infection,
ETBF Min tumors had significantly less mtDNA content
than mock or ETBF Min epithelium or mock Min or
ETBF Msh2l/lVCMin tumors (Fig. 1c, d). mtDNA
content in mock Min tumors was not significantly
different from the mock epithelium at either time point.
At 4 weeks post-ETBF mtDNA content in ETBF
Msh2l/lVCMin tumors was slightly reduced depending
on the locus examined, but was unchanged or in-
creased at the 8-week time point (Fig. 1d). mtDNA
content in ETBF epithelium was also partially reduced
at 4 weeks, but returned to normal levels at 8 weeks
post-ETBF. Altogether, these data demonstrate that
inflammation-induced tumors with Polg promoter
CpG-island DNA hypermethylation have reduced Polg
gene expression and mtDNA content.
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Fig. 1 Tumors with promoter DNA methylation and reduced expression of Polg have reduced mitochondrial DNA content. a qMSP of bisulfite-
treated DNA from indicated tissue 4 or 8 weeks post-infection using methylation-specific primers in promoter CpG islands of indicated genes.
Mean ± SEM. N = 4–5 for epithelium, N = 5–9 for tumors. *P < 0.05 compared with mock epithelium. #P < 0.05 compared to ETBF Min epithelium
and mock Min and ETBF Msh2l/lVCMin tumors. b Polg gene expression by qPCR relative to mock epithelium. Mean ± SEM. N = 4–8 for epithelium,
N = 6–12 for tumors, asterisk and number sign as in a. DNA from tissue (c) 4 weeks or (d) 8 weeks post-infection was used in qPCR assays with
primer sets specific for two different regions of mitochondrial DNA or the genomic ApoB. Mean ± SEM. N = 4–5 for epithelium, N = 5–9 for
tumors, asterisk and number sign as in a
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Inflammation-induced tumors with wildtype MSH2 have
fewer mitochondria
Mitochondria have multiple copies of mtDNA, and the
number can vary between cell types [10], suggesting that
the decrease in mtDNA content in the ETBF tumors
could be from decreased number of mtDNA copies per
mitochondria or decreased numbers of total mitochon-
dria in the tumors. Therefore, we used transmission
electron microscopy (TEM) to image mitochondria in
tumors from our mouse model. Because of size limita-
tions of TEM, we used tissues from mice 4 weeks
post-infection when tumors are still relatively small.
Since mitochondria can be relocalized inside cells in re-
sponse to stress, it was important to use control tissue
that was undergoing similar inflammation-induced stress
[24]. Therefore, ETBF Msh2l/lVCMin tumors are the
best comparison tissue for ETBF Min tumors. TEM
images of ETBF Min tumors had fewer mitochondria
than ETBF Msh2l/lVCMin tumors (2.0 versus 9.6 mito-
chondria per image, respectively) (Fig. 2). There were no
obvious structural differences in the mitochondria that
were present between the two different tumor types.
This finding suggests that reduced expression of Polg by
inflammation-induced DNA hypermethylation results in
fewer mitochondria in tumors although some are still
present and likely necessary for cell survival.
Altered expression of metabolic genes and metabolite
levels in inflammation-induced tumors
Altered mitochondrial function has been associated with
increased aerobic glycolysis [6]. To determine the
alterations in metabolic gene expression in ETBF Min
tumors versus mock Min epithelium, we first used a
PCR array for detecting expression of genes involved in
glucose metabolism as well as screened additional candi-
dates by qPCR. Using a two-fold cutoff, three genes on the
array had increased expression in inflammation-induced
tumors (Phosphoribosyl pyrophosphate synthetase 1-Like 1
Prps1l1; Hexokinase 3 - Hk3; Glycogen phosphorylase,
muscle associated - Pygm) and 17 genes had decreased
expression on the PCR array (Additional file 1: Table S2).
We verified expression alterations of genes with the
greatest fold change (Glucokinase –Gck; Aldolase,
fructose-bisphosphate B – Aldob; Prps1l1; Hk3) by
qRT-PCR, and all expression changes were validated
(Fig. 3a and Additional file 1: Figure S1A). To determine
which gene expression changes may be associated with re-
duced expression of Polg and reduced mitochondria, we
also performed qRT-PCR using mock Min tumors and
ETBF-induced Msh2l/lVCMin tumors, which have higher
levels of Polg expression and mtDNA content than ETBF
Min tumors. Hif1a (Hypoxia inducible factor 1 alpha),
Glut1 (glucose transporter 1), and Hk2 had increased
expression in ETBF Min tumors relative to mock Min
epithelium as well as relative to mock Min and ETBF
Msh2l/lVCMin tumors (Fig. 3a). None of these genes had
significant increases in expression in the other tumor
types relative to mock Min epithelium. Hif1a expression
was also increased in mock Msh2l/lVCMin epithelium and
ETBF epithelium from Min and Msh2l/lVCMin mice rela-
tive to mock Min epithelium. Expression of 6-phophofruc-
tose-2-kinas/fructose2,6-biphosphatase 3 (Pfkfb3), the only
isoform of Pfkb that is induced by inflammatory stimuli
and hypoxia, was significantly increased in all tumors
assayed relative to mock Min epithelium and was signifi-
cantly higher in ETBF Min tumors than mock Min or
ETBF Msh2l/lVCMin tumors (Fig. 3a). Pfkfb3 expression
was not altered in ETBF epithelium from either genotype.
Gck expression was reduced in all tumor types, but was
significantly lower in ETBF Min tumors compared to the
other tumor types (Fig. 3a). Gck expression was also de-
creased in ETBF Msh2l/lVCMin epithelium. Interestingly,
all of the expression changes in ETBF Min tumors are as-
sociated with increased glycolytic flux [5, 25]. Stabilization
Fig. 2 Inflammation-induced tumors with wildtype MSH2 have fewer mitochondria. One tumor each from mice of the indicated genotypes
4 weeks post-ETBF infection was imaged by transmission electron microscopy. Red asterisk indicates mitochondria. Five images at the same
magnification were taken per sample in a blinded fashion, and the numbers of mitochondria per image were counted. Mean ± SEM. *P < 0.05
Maiuri et al. Cancer & Metabolism  (2018) 6:9 Page 6 of 11
of HIF1α protein and activation of AKT (AKT serine/
threonine kinase 1) are common occurrences in tumors
and both of them can alter the expression of metabolic
genes [26]. However, by western blot, total HIF1α and
phosphorylated AKT were elevated to similar levels in
ETBF and mock Min tumors relative to mock Min epithe-
lium (Additional file 1: Figure S1B).
To more directly determine if the inflammation-induced
tumors have altered metabolism, we assayed metabolite
levels in epithelium and tumors. We focused on
inflammation-induced tumors from Min andMsh2l/lVCMin
mice because these tumors were undergoing similar
inflammation-induced stress but had different Polg and
mtDNA levels. While there was no change in glucose levels,
the levels of glucose-6-phosphate (G-6P) were higher in
ETBF Min tumors than mock Min epithelium (Fig. 3b).
G-6P levels in ETBF Msh2l/lVCMin tumors were unaltered
relative to mock Msh2l/lVCMin epithelium. Pyruvate levels
were increased similarly in ETBF Min and Msh2l/lVCMin
tumors relative to their respective epithelium (Fig. 3b).
Lactate and the tricarboxylic acid (TCA) metabolites
(citrate, fumarate, succinate, malate) were elevated in
both tumor types relative to their respective epithe-
lium (Fig. 3b). However, levels of these metabolites
were significantly higher in ETBF Msh2l/lVCMin
tumors relative to ETBF Min tumors. Altogether,
these data suggest that both types of tumors have al-
tered metabolite levels relative to their respective
mock epithelium, but that ETBF Min tumors have in-
creased G-6P and lower mitochondrial metabolites
than ETBF Msh2l/lVCMin tumors.
Tumoroids derived from inflammation-induced tumors
have increased glucose uptake
The increased expression of genes related to glycolytic
flux as well as increased G-6P metabolite levels suggest
that inflammation-induced tumors have increased glu-
cose uptake. To be able to directly assay glucose uptake
in tumor cells, we derived organoids from tumors from
mock or ETBF-infected Min mice (tumoroids) as well as
organoids from mock colon epithelium (colonoids).
Since tumoroids and colonoids only consist of tumor or
epithelial cells, respectively, they provide a reductionist
approach to examining cellular changes without other
cells that are normally present in the mucosal layer of
the colon [27]. Colonoids formed characteristic budding
structures, whereas mock and ETBF tumoroids formed
cystic structures that were similar in appearance to each
other (Fig. 4a). ETBF tumoroids proliferated significantly
faster than mock tumoroids as demonstrated by in-
creased DNA content per well of tumoroids at days 4, 5,
and 6 post-plating for ETBF relative to mock tumoroids
(Fig. 4b). We verified that ETBF tumoroids maintain re-
duced Polg expression relative to colonoids and mock
tumoroids (Fig. 4c). We then verified that ETBF tumor-
oids have the increased Polg promoter CpG-island
methylation present in ETBF Min tumors by perform-
ing qMSP on isolated DNA. ETBF tumoroids did
have higher levels of DNA methylation at the Polg
promoter than colonoids and mock tumoroids, but
not at the Gapdh promoter, which does not undergo
inflammation-induced DNA hypermethylation (Fig. 4d).
Furthermore, ETBF tumoroids had lower levels of
mtDNA than colonoids and mock tumoroids consist-
ent with our previous data (Fig. 4e). Interestingly,
ETBF tumoroids had increased glucose uptake relative
to mock tumoroids (Fig. 4f; measured 5 days after
plating). To confirm these results by a different assay,
glucose levels in the media that the tumoroids were
growing in were measured and normalized to the
a
b
*
#
*
* *
#
#
*
*
*
*
#
*
#
*
*
*
*
Hif1a Glut1 Hk2 Gck PFKFB3
0
2
4
6
1
9
10
11
re
la
tiv
e 
ex
pr
es
si
on
Mock Min epithelium
ETBF Min tumor
ETBF Msh2 l/lVCMin tumor
Mock Min tumor
Mock Msh2 l/lVCMin epithelium
ETBF Min epithelium
ETBF Msh2 llVCMin epithelium
#
* *
*
*
*
* *
*
## #
***
#
*
*
Gl
uc
os
e
Gl
uc
os
e-
6
-p
ho
sp
ha
te
Py
ru
va
te
La
cta
te
Ci
tra
te
Fu
m
ar
at
e
Su
cc
ina
te
M
ala
te
0
5
10
1
re
la
tiv
e 
m
et
ab
ol
ite
 le
ve
ls
Mock Min epithelium
Mock Msh2 l/lVCMin epithelium
ETBF Msh2 l/lVCMin tumor
ETBF Min tumor
*
Fig. 3 Inflammation-induced tumors have altered metabolism. a
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DNA content of the tumoroids. ETBF tumoroids
depleted the media of more glucose than mock
tumoroids at days 4, 5, and 6 post-plating (Fig. 4g).
Since aerobic glycolysis results in increased produc-
tion and secretion of lactate, we measured lactate
levels in the media and normalized these values to
DNA content. Lactate secretion by ETBF tumoroids
was more than mock tumoroids at days 4, 5, and 6
post-plating (Fig. 4h). Changes in glucose levels in the
media were undetectable at 2 days post-plating, and
glucose and lactate levels were not different between
the tumoroid types at 3 days post-plating. These
findings demonstrate that epigenetic changes persist
in tumoroids and that tumoroids derived from
inflammation-induced tumors with reduced Polg ex-
pression have increased proliferation, glucose uptake,
and lactate secretion than mock tumoroids.
Reduction of Polg expression increases glucose uptake
and resistance to oxidative stress in mock tumoroids
Tumors have many epigenetic and other types of alter-
ations compared to normal epithelium. To determine if
reduced Polg expression directly affects glucose uptake,
we first knocked down Polg in colonoids derived from
the epithelium of WT-uninfected mice. shRNA knock-
down of Polg resulted in decreased Polg expression and
reduced mtDNA (Additional file 1: Figure S2A&B).
However, glucose uptake was similar in nontarget (NT)
and Polg knockdown (KD) colonoids suggesting that re-
duced expression of Polg in WT colonoids is not sufficient
to alter glucose uptake (Additional file 1: Figure S2C).
To determine if reduced Polg expression is sufficient
to alter metabolism in tumor cells, we knocked down
Polg in mock tumoroids. Polg KD tumoroids had less
Polg expression than NT KD tumoroids (Fig. 5a). The
Polg KD tumoroids also had less mtDNA content than
NT tumoroids and similar mtDNA content as ETBF
tumoroids (Fig. 5b). Polg KD tumoroids had significantly
increased glucose uptake and lactate secretion relative to
NT tumoroids, but less than ETBF tumoroids suggesting
that, at least in part, the increased glucose uptake and
lactate secretion in ETBF tumoroids is due to the pro-
moter DNA methylation and reduced expression of Polg
(Fig. 5c, d).
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Mitochondria are major intracellular producers of
reactive oxygen species (ROS) and are susceptible to
oxidative damage [28]. They also play a key role in initi-
ation and execution of apoptosis. Therefore, we hypoth-
esized that tumoroids with fewer mitochondria would be
more resistant to oxidative stress than those with normal
levels. We determined that ETBF and Polg KD tumor-
oids are more resistant to oxidative stress than NT KD
tumoroids by measuring cell viability 72 h after mock or
0.5 mM hydrogen peroxide (H2O2) treatment (Fig. 5d).
Altogether, these findings demonstrate that KD of
Polg reduces mtDNA content in both colonoids and
tumoroids and increases glucose uptake, lactate secre-
tion, and resistance to oxidative stress specifically in
tumoroids.
Discussion
It is well established that inflammation can induce silen-
cing of genes by promoter CpG-island DNA hyperme-
thylation, and this methylation, if it occurs in the
promoters of tumor suppressor genes, can participate in
tumorigenesis [29]. Tumorigenesis can also be initiated
by mechanisms independent of chronic inflammation.
Whether inflammation-driven DNA methylation events
result in tumors that are phenotypically different from
tumors whose formation is not directly from chronic in-
flammation is not well understood. Here, we uniquely
demonstrate that inflammation-driven DNA methylation
and gene silencing of Polg in murine colon tumors
results in tumors with fewer mitochondria and altered
metabolism in comparison to non-inflammation-induced
tumors. Furthermore, tumoroids derived from these two
types of tumors retain their DNA methylation, mitochon-
dria, and metabolic differences. Using the tumoroids as a
manipulatable system, we demonstrate that increased glu-
cose uptake, lactate secretion, and resistance to oxidative
stress in inflammation-induced colon tumors are, at least
in part, due to decreased Polg expression.
Human colorectal cancer tissue has lower mtDNA
copy number than surrounding normal tissue, and the
copy number negatively correlates with disease progres-
sion [30–32]. There is also evidence of alterations in
mitochondrial function in the epithelium of patients with
inflammatory bowel disease, a condition that increases
risk for developing colon cancer [33]. However, in these
studies, which use human primary samples, it is unclear if
decreased mtDNA is directly involved in disease progres-
sion or is a consequence of the disease itself. Here, we
demonstrate that, in the setting of inflammation-induced
tumors, decreases in mtDNA copy and in numbers of
mitochondria are directly associated with increased glu-
cose uptake, lactate secretion, and resistance to oxidative
stress.
The cause-effect relationship between glycolysis and
cancer is controversial. Mitochondria produce ATP
through OXPHOS and synthesize key molecules needed
for cellular proliferation. Some level of functional mito-
chondria and mtDNA is necessary for the survival of
cancers cells [26]. However, dysfunction of mitochondria
in tumor cells through mtDNA mutations and/or reduc-
tion in mtDNA copy number alters OXPHOS resulting
in increased reliance on aerobic glycolysis [6]. Upregula-
tion of glycolysis produces ATP to compensate for
decreased ATP production by mitochondria. Glycolysis
also provides intermediates for macromolecular biosyn-
thesis and redox homeostasis [34]. These connections
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Fig. 5 Reduced Polg expression increases glucose uptake and
resistance to oxidative stress. a Polg gene expression in nontarget
(NT) or Polg knockdown (KD) mock tumoroids by qPCR relative to
NT organoids. Mean ± SEM. The data is from three independent
experiments each with two biological replicates. *P < 0.05. b DNA
from tumoroids as in a was used in qPCR assays with primer sets
specific for two different regions of mitochondrial DNA or the
genomic ApoB. Mean ± SEM. The data is from three independent
experiments each with two biological replicates. *P < 0.05 compared
to NT. c Glucose uptake by tumoroids derived as in a normalized
to protein concentration. Mean ± SEM. The data is from three
independent experiments each with three biological replicates.
*P < 0.05 compared to NT. #P < 0.05 compared to Polg KD. d Lactate
levels in media from wells with tumoroids as in a normalized to
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suggest that alterations in mitochondrial functions have
a role in initiating or sustaining some tumors [6]. The
loss of Polg expression in our system directly results in
reduced mitochondria and a shift towards increased gly-
colysis. Importantly, the DNA methylation, reduced Polg
expression, and decrease in number of mitochondria
occur early in the tumorigenesis process (at the earliest
time point when we can macroscopically detect tumors)
and occur to some extent in all inflammation-induced
wildtype MSH2 tumors, we have tested in our model.
The strong selective pressure for this process suggests
that it results in a survival benefit for cells that harbor
DNA hypermethylation of the promoter of Polg.
Mitochondria are the major producer of intracellular
ROS and reactive nitrogen species (RNS). Damage of
mitochondria and impairment of mitochondrial respira-
tory function enhances ROS release into the cytoplasm
[28]. Mitochondria also play a significant role in the in-
duction of apoptosis [35]. While ROS can play a positive
role in tumorigenesis, ROS levels above the antioxidant
capability of the tumor cells are detrimental [36]. Having
fewer mitochondria present in cells at sites of chronic
inflammation would result in less mitochondrial damage
and therefore potentially less intracellular ROS produc-
tion and reduced induction of apoptosis. On the other
hand, increased redox potential of ETBF Min tumors
could account for the increased resistance to ROS. Even
though glucose uptake is higher in ETBF than mock
tumoroids, the levels of glucose in tumor tissues are not
changed significantly suggesting that the additional glu-
cose is rapidly metabolized. Only the upstream metabol-
ite, G-6P, is higher in ETBF Min tumors. The levels of
the TCA cycle intermediates and lactate are lower in
ETBF Min tumors, and the levels of pyruvate are not
changed. The glucose could be metabolized through the
pentose phosphate pathway rather than glycolysis, which
would result in production of the reducing agent
NADPH (nicotinamide adenine dinucleotide phosphate)
[34]. However, we found no differences in NADPH or
reduced glutathione (GSH) levels between different
tumor or tumoroid types (data not shown). While the
exact mechanism of increased resistance to ROS needs
to be further elucidated, we demonstrate that tumoroids
with reduced expression of Polg (and consequently fewer
mitochondria) are more resistant to oxidative stress
suggesting a possible mechanism for the selective advan-
tage for epigenetic silencing of Polg during chronic
inflammation-induced tumorigenesis.
Conclusions
Polg DNA methylation changes in inflammation-induced
colon tumors make them metabolically different from
non-inflammation-induced tumors and more resistant to
oxidative stress. Understanding the metabolic differences
and the role epigenetics plays in establishing and main-
taining these differences is important for developing
strategies to best treat cancers in patients that are
caused by different etiologies. For example, pursuing dif-
ferences in metabolism by using glycolytic inhibitors
against cancer cells with mitochondrial defects may
allow for targeted oncology therapeutics.
Additional file
Additional file 1: Figure S1. Additional gene and protein expression in
mock and ETBF-induced tumors. A) Gene expression by qPCR relative to
mock epithelium from indicated tissue 8 weeks post-infection.
Mean ± SEM. N = 6. *P < 0.05 compared with mock Min epithelium.
#P < 0.05 compared to Msh2l/lVCMin ETBF tumors. B) Western blots were
run using protein isolated from indicated tissue 8 weeks post-infection.
Blots are representative of two independent sets of biological replicates.
Figure S2. Polg knockdown in colonoids derived from normal epithelium
does not alter glucose uptake. A) Polg gene expression by qRT-PCR
relative to nontarget (NT) knockdown colonoids derived from wt
epithelium. Bar represents mean ± SEM. *P < 0.05. B) DNA from organoids
as in A was used in qPCR assays with primer sets specific for a region of
mitochondrial DNA or the genomic ApoB. Bars indicate mean ± SEM.
*P < 0.05. C) Glucose uptake by tumoroids derived as in A. Mean ± SEM.
NS not significant. Table S1. Primer sequences for qMSP and mtDNA
content and assays used for TaqMan gene expression. Table S2. Fold
change in expression by RT2 Profiler Glucose Metabolism PCR Array.
(DOCX 3724 kb)
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